Literature DB >> 4818776

Inhibition of prolactin secretion by ergolines.

J A Clemens, C J Shaar, E B Smalstig, N J Bach, E C Kornfeld.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4818776     DOI: 10.1210/endo-94-4-1171

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


× No keyword cloud information.
  10 in total

1.  The interactions of bromocriptine and lergotrile with dopamine and alpha-adrenergic receptors.

Authors:  J Y Lew; F Hata; T Ohashi; M Goldstein
Journal:  J Neural Transm       Date:  1977       Impact factor: 3.575

2.  Differential behavioral and biochemical effects of four dopaminergic agonists.

Authors:  G Gianutsos; K E Moore
Journal:  Psychopharmacology (Berl)       Date:  1980       Impact factor: 4.530

3.  Interactions between domperidone and ropinirole, a novel dopamine D2-receptor agonist.

Authors:  C de Mey; D Enterling; I Meineke; S Yeulet
Journal:  Br J Clin Pharmacol       Date:  1991-10       Impact factor: 4.335

4.  Possible influence of prolactin on intestinal hypertrophy in pregnant and lactating rats.

Authors:  J R Mainoya
Journal:  Experientia       Date:  1978-09-15

5.  Luteal 20alpha-hydroxy steroid dehydrogenase and the formation of delta4-3-oxo steroids in the rat after weaning or treatment with 2-bromo-alpha-ergocryptine during lactation.

Authors:  R G Rodway; N J Kuhn
Journal:  Biochem J       Date:  1975-12       Impact factor: 3.857

Review 6.  Anti-parkinsonian drugs today.

Authors:  N P Quinn
Journal:  Drugs       Date:  1984-09       Impact factor: 9.546

7.  Effect of lergotrile on 3,4-dihydroxyphenylacetic acid (DOPAC) concentration and dopamine turnover in rat brain.

Authors:  R W Fuller; K W Perry
Journal:  J Neural Transm       Date:  1978       Impact factor: 3.575

8.  Dopaminergic modulation of adenylate cyclase stimulation by vasoactive intestinal peptide in anterior pituitary.

Authors:  P Onali; J P Schwartz; E Costa
Journal:  Proc Natl Acad Sci U S A       Date:  1981-10       Impact factor: 11.205

Review 9.  Prolactin-lowering and -releasing drugs. Mechanisms of action and therapeutic applications.

Authors:  E E Müller; V Locatelli; S Cella; A Peñalva; A Novelli; D Cocchi
Journal:  Drugs       Date:  1983-04       Impact factor: 9.546

10.  Enhancement by prolactin of carcinogen induced mammary cancerigenesis in the male rat.

Authors:  C W Welsch; G Louks; D Fox; C Brooks
Journal:  Br J Cancer       Date:  1975-10       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.